Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile

Abstract

Botulinum toxin (BoNT) formulations are being used for a variety of medical applications. The use of BoNT preparations is continuously expanding with new formulations and indications. Of the seven antigenically distinct BoNTs, only two serotypes, type A and type B are commonly available for therapeutic use. The four available BoNT products are not equivalent and the knowledge of their formulations is crucial for product selection, avoidance of medication errors, therapeutic efficacy and safety. Generally, BoNT injection is a safe procedure when administered by an experienced injector. Side effects are always transient, and in the majority of cases they are mild and tolerable.

Keywords

AbobotulinumtoxinA - OnabotulinumtoxinA - IncobotulinumtoxinA - RimabotulinumtoxinB

• References

• 1 Pellett S. Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol 2012; 15 (3) 292-299
• 2 Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29 (23) 1761-1768
• 3 Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002; 18 (6, Suppl) S119-S124
• 4 Wortzman MS, Pickett A. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 2009; 29 (6, Suppl) S34-S42
• 5 BOTOX (onabotulinumtoxinA) [package insert] . Irvine, CA: Allergan, Inc; 2011
• 6 Dysport (abobotulinumtoxinA) [package insert] . Wrexham, UK: Ipsen Biopharm, Ltd; 2010
• 7 XEOMIN (incobotulinumtoxinA) [package insert] . Greensboro, NC: Merz Pharmaceuticals, LLC; 2011
• 8 MYOBLOC (rimabotulinumtoxinB) [package insert] . South San Francisco, CA: Solstice Neurosciences, Inc.; 2010
• 9 183 Ongoing current clinical trials on botulinum neurotoxin. Available at: https://clinicaltrials.gov/ct2/results?term=botulinum+toxin&recr=Open . Accessed July 7, 2015
• 10 Naumann M, So Y, Argoff CE , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1707-1714
• 11 Naumann M, Dressler D, Hallett M , et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 2013; 67: 141-152
• 12 Setler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55 (12) (Suppl. 05) S22-S28
• 13 Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013; 28 (13) 1775-1783
• 14 Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009; 40 (3) 374-380
• 15 Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 2008; 41 (4) 897-902
• 16 Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy 2013; 33 (3) 304-318
• 17 Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015; 15 (1) 1-9
• 18 Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 2013; 120 (2) 275-290
• 19 Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26 (2) e1-e9
• 20 Schulte-Baukloh H, Bigalke H, Miller K , et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol 2008; 70: 133-136 , discussion 415
• 21 Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?. Biologics 2010; 4: 325-332